Printer Friendly

Research and Markets: Fabry Disease Global Clinical Trials Review, H1, 2012.

DUBLIN -- Research and Markets ( has announced the addition of GlobalData's new report "Fabry Disease Global Clinical Trials Review, H1, 2012" to their offering.

GlobalData's clinical trial report, Fabry Disease Global Clinical Trials Review, H1, 2012" provides data on the Fabry Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fabry Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fabry Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.


- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Buy:

- Understand the dynamics of a particular indication in a condensed manner

- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

- Obtain discontinued trial listing for trials across the globe

- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

For more information visit

Source: GlobalData
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 14, 2012
Previous Article:Research and Markets: Power-One Aurora Trio 10KW PV Inverter Reverse Costing Analysis.
Next Article:Research and Markets: Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2012.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters